Why Danaher (DHR) Is Drawing Attention Now
Danaher (DHR) is back on many watchlists after a period of weaker share performance, including a 13% decline over the past month and a 21% decline over the past 3 months.
See our latest analysis for Danaher.
At a share price of $181.52, Danaher’s recent 13% 1 month share price decline and 21% 3 month share price decline extend a tougher run, while the 1 year total shareholder return of 11% and 5 year total shareholder return of 7% indicate pressure on longer term holders.
If this pullback has you reassessing opportunities in healthcare and diagnostics, it can be useful to compare Danaher with other potential growth stories across 34 healthcare AI stocks.
With Danaher trading at $181.52 and showing a 19% intrinsic discount plus a large gap to the average analyst target, you have to ask: is this a reset that offers upside, or is the market already pricing in future growth?
Most Popular Narrative: 31.5% Undervalued
With Danaher shares at $181.52 versus a narrative fair value of $264.91, the gap reflects a view that current pricing does not fully capture future cash flows under this framework.
The sustained advancement of precision medicine and personalized therapies, including new AI-assisted diagnostic solutions and groundbreaking launches in genomics (like support for in vivo CRISPR therapies), positions Danaher's technology portfolio to capture higher-margin growth and drive long-term EBITDA expansion.
Curious what kind of revenue trajectory and margin rebuild would need to play out to support that valuation gap? The narrative leans on recurring consumables, rising profitability and a richer earnings multiple that sits above sector averages, all tied together by a specific discount rate and multi year earnings bridge.
Result: Fair Value of $264.91 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, shifts in China healthcare policy and any prolonged softness in early stage biotech funding could quickly challenge the upbeat Masimo and earnings growth narrative.
Find out about the key risks to this Danaher narrative.
Another Way To Look At Danaher’s Valuation
The SWS DCF model estimates Danaher’s future cash flows at $224.19 per share, compared to the current price of $181.52. This implies the shares trade at a 19% discount on this framework. That is less generous than the 31.5% undervaluation implied by the narrative fair value. Which story do you feel is closer to your own expectations?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
If the mix of risks and potential upside here feels finely balanced, it may be worth acting promptly and testing the numbers yourself. To see what is driving the optimism and which rewards stand out most clearly, review the 3 key rewards
Looking for more investment ideas?
If Danaher has sharpened your thinking, do not stop here. Broaden your watchlist with a few carefully filtered sets of companies that might suit your style.
- Target consistent cash generators by checking companies that appear in the solid balance sheet and fundamentals stocks screener (39 results).
- Hunt for opportunities with pricing that looks appealing relative to quality using the 61 high quality undervalued stocks.
- Spot companies the crowd may have overlooked by scanning the screener containing 26 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com